Greylin Investment Mangement Inc. increased its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 36.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 294,495 shares of the company’s stock after buying an additional 79,300 shares during the period. Teva Pharmaceutical Industries Limited comprises approximately 2.3% of Greylin Investment Mangement Inc.’s portfolio, making the stock its 11th largest position. Greylin Investment Mangement Inc.’s holdings in Teva Pharmaceutical Industries Limited were worth $9,783,000 as of its most recent SEC filing.
A number of other hedge funds also recently added to or reduced their stakes in the company. Guggenheim Capital LLC increased its stake in Teva Pharmaceutical Industries Limited by 1.1% in the fourth quarter. Guggenheim Capital LLC now owns 40,276 shares of the company’s stock valued at $1,460,000 after buying an additional 446 shares in the last quarter. Lincluden Management Ltd. increased its stake in Teva Pharmaceutical Industries Limited by 7.8% in the fourth quarter. Lincluden Management Ltd. now owns 58,854 shares of the company’s stock valued at $2,133,000 after buying an additional 4,272 shares during the period. Migdal Insurance & Financial Holdings Ltd. increased its stake in Teva Pharmaceutical Industries Limited by 21.3% in the fourth quarter. Migdal Insurance & Financial Holdings Ltd. now owns 4,564,560 shares of the company’s stock valued at $165,461,000 after buying an additional 801,106 shares during the period. UBS Asset Management Americas Inc. increased its stake in Teva Pharmaceutical Industries Limited by 150.7% in the fourth quarter. UBS Asset Management Americas Inc. now owns 2,004,760 shares of the company’s stock valued at $72,672,000 after buying an additional 1,205,253 shares during the period. Finally, HighPoint Advisor Group LLC increased its stake in Teva Pharmaceutical Industries Limited by 19.3% in the fourth quarter. HighPoint Advisor Group LLC now owns 6,250 shares of the company’s stock valued at $219,000 after buying an additional 1,010 shares during the period. 56.20% of the stock is currently owned by institutional investors.
Shares of Teva Pharmaceutical Industries Limited (TEVA) traded down 13.26% during mid-day trading on Friday, reaching $20.60. 93,317,085 shares of the company traded hands. Teva Pharmaceutical Industries Limited has a 52-week low of $20.41 and a 52-week high of $55.79. The company has a market capitalization of $20.93 billion, a P/E ratio of 264.10 and a beta of 0.46. The firm’s 50 day moving average price is $32.05 and its 200-day moving average price is $32.28. Teva Pharmaceutical Industries Limited also was the target of some unusual options trading on Thursday. Stock investors bought 66,716 put options on the company. This is an increase of approximately 864% compared to the average volume of 6,922 put options.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) last issued its quarterly earnings data on Thursday, August 3rd. The company reported $0.99 EPS for the quarter, missing the Zacks’ consensus estimate of $1.06 by $0.07. The company had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.72 billion. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.18%. The business’s revenue was up 12.9% on a year-over-year basis. During the same period in the prior year, the company posted $1.25 EPS. Equities analysts predict that Teva Pharmaceutical Industries Limited will post $4.65 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This piece of content was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://stocknewstimes.com/2017/08/05/teva-pharmaceutical-industries-limited-nyseteva-stake-raised-by-greylin-investment-mangement-inc-updated.html.
TEVA has been the subject of several analyst reports. Vetr upgraded shares of Teva Pharmaceutical Industries Limited from a “sell” rating to a “hold” rating and set a $32.27 target price for the company in a research note on Wednesday, June 28th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $38.00 target price (down from $42.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Monday, May 15th. Zacks Investment Research upgraded shares of Teva Pharmaceutical Industries Limited from a “sell” rating to a “hold” rating in a research note on Monday, April 17th. Piper Jaffray Companies reiterated a “hold” rating and issued a $23.00 target price on shares of Teva Pharmaceutical Industries Limited in a research note on Friday. Finally, Wells Fargo & Company restated a “market perform” rating on shares of Teva Pharmaceutical Industries Limited in a research report on Saturday, April 29th. One research analyst has rated the stock with a sell rating, twenty-two have given a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $39.81.
About Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.
